Harinder S. Garewal

20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only wit…

Twenty-one unselected patients with refractory chronic anemias of various etiologies were treated with danazol, a synthetic attenuated androgen. All had previously failed treatment with hematinics, androgens, corticosteroids, high-dose intr…

In Reply.— Ambriz et al report on their experience with danazol in mild to moderate hemophilia. No significant increase in factor levels was noted in 18 of 20 patients receiving 800 mg/day of danazol. Two patients showed modest increases (6…

Danazol was given orally at a dose of 600 mg/day to six hemophiliacs for eight to 14 weeks. All patients showed a significant decrease in activated partial thromboplastin time (APTT) beginning with the first measurement (two weeks) and pers…